Pfizer, Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts
Pfizer, Inc. (NYSE:PFE) has been assigned an average recommendation of “Hold” from the twenty-four research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $37.82.
PFE has been the topic of a number of recent research reports. Sanford C. Bernstein restated a “buy” rating and issued a $35.00 price target on shares of Pfizer in a research report on Monday, April 24th. Societe Generale restated a “neutral” rating and issued a $36.00 price target on shares of Pfizer in a research report on Thursday, March 23rd. Jefferies Group LLC restated a “hold” rating and issued a $35.00 price target (up from $34.00) on shares of Pfizer in a research report on Friday, July 14th. BidaskClub downgraded shares of Pfizer from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th.
ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/19/pfizer-inc-nysepfe-given-consensus-rating-of-hold-by-analysts.html.
Several institutional investors have recently made changes to their positions in the company. Asset Planning Services Ltd. boosted its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. boosted its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. boosted its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Pfizer during the first quarter valued at about $121,000. Finally, Cascade Investment Advisors Inc. boosted its position in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares in the last quarter. 69.95% of the stock is currently owned by institutional investors.
Shares of Pfizer (PFE) opened at 33.36 on Wednesday. The company has a 50-day moving average of $33.13 and a 200-day moving average of $33.25. Pfizer has a 12 month low of $29.83 and a 12 month high of $37.39. The stock has a market capitalization of $199.09 billion, a PE ratio of 28.08 and a beta of 1.01. Pfizer also saw unusually large options trading activity on Tuesday. Traders purchased 21,983 put options on the company. This represents an increase of 351% compared to the typical daily volume of 4,871 put options.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The company had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. During the same period last year, the firm posted $0.67 EPS. The company’s revenue for the quarter was down 1.7% on a year-over-year basis. On average, equities research analysts expect that Pfizer will post $2.55 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be paid a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.84%. Pfizer’s dividend payout ratio is currently 108.48%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.